Gapping up
In reaction to earnings/guidance:
- SSTI +18.2%, ENPH +13%, GRMN +7.5%, HLF +5.5%, FVRR +5.4%, LZB +4.6%, TPH +4.3%, HQY +4.3%, SCPL +4.2%, SAH +3.6%, FANG +3.2%, TIVO +3.1%, RPAI +3.1%, ATHM +2.7%, DVN +2.3%, DISH +1.9%, AG +1.7%, ONE +1.6%, RCEL +1.6%, GSS +1.4%, TRTX +1.2%, QTS +1.1%
Other news:
- BBBY +4.6% (discusses recent transactions and $1 bln capital allocation strategy)
- IAG +1% (reports total attributable proven and probable reserves)
- INCY +1% (announces pivotal Phase 3 study from the TRuE-AD clinical trial program met its primary and secondary endpoints)
Analyst comments:
- TSLA +7.4% (target raised to a Street high $928 from $729 at Piper Sandler)
- ALEC +3.5% (initiated with a Buy at Stifel)
- NVDA +1.5% (upgraded to Outperform from Mkt Perform at Bernstein)
- DNLI +1.5% (initiated with a Hold at Stifel)
- PRVL +1.2% (initiated with an Outperform at Oppenheimer)